NCT06389500View on ClinicalTrials.gov

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Biliary Tract Cancer
Interventions
DRUG

Adebrelimab

Adebrelimab, IV

DRUG

Lenvatinib

Lenvatinib, PO

PROCEDURE

Hepatic Arterial Infusion Chemotherapy

GC regimen±5-FU

All Listed Sponsors
lead

Harbin Medical University

OTHER

NCT06389500 - HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter